Margarida Maia, PhD,  science writer—

Patients with myasthenia gravis (MG) and self-reactive antibodies against the muscle-specific kinase (MuSK) protein are more likely to have poorer outcomes when experiencing a myasthenic crisis than other MG patients, a study suggests. Outcomes linked to MuSK antibody production include longer periods of hospitalization or admittance to intensive care,…

A new type of plasma exchange treatment, called double-filtration plasmapheresis (DFPP), may be effective and safe for short-term relief of myasthenia gravis (MG) symptoms, a review study has found. These findings may have important clinical implications, especially for patients with severe or critical MG, the researchers noted. The review,…